Entropy Neurodynamics

Entropy Neurodynamics (ASX: ENP, formerly Tryp Therapeutics) is a clinical-stage biotech developing psilocin therapies w/ psychotherapy for unmet medical needs.

[Entropy Neurodynamics @Entropy_Neuro]

ICYMI: 📢 @Entropy_Neuro (#ASX: $ENP) secures South African patent for proprietary psilocin formulations through 2043
⚡ Strengthens TRP-8803's IP protection, supporting future licensing & strategic partnerships
#biotech #health
https://t.co/1BCTtzQ32N

[Entropy Neurodynamics @Entropy_Neuro]

ICYMI: 🔬Entropy Neurodynamics secured a South African patent for proprietary psilocin crystalline forms, strengthening the IP portfolio supporting TRP-8803. Protection extends to September 2043.

Read more: https://t.co/swJahqu1oU

#ASX $ENP #Biotech

[Entropy Neurodynamics @Entropy_Neuro]

From the @InvestorStream_ desk:
📢 @Entropy_Neuro (#ASX: $ENP) secures South African patent for proprietary psilocin formulations through 2043
⚡ Strengthens TRP-8803's IP protection, supporting future licensing & strategic partnerships
#biotech #health
https://t.co/1BCTtzQ32N

[Entropy Neurodynamics @Entropy_Neuro]

🔬Entropy Neurodynamics secured a South African patent for proprietary psilocin crystalline forms, strengthening the IP portfolio supporting TRP-8803. Protection extends to September 2043.

Read more: https://t.co/swJahquzes

#ASX $ENP #Biotech

[Entropy Neurodynamics @Entropy_Neuro]

ICYMI: A strong quarter for Entropy Neurodynamics $ENP
✅ 100% clinical response, 50% remission in Phase 2 BED study (6 patients)
✅ 72-patient, 8-indication study approved
✅ US clinical pathway advanced with UCSF
✅ BioCina manufacturing agreement
READ: https://t.co/EiDmxgFufE

[Entropy Neurodynamics @Entropy_Neuro]

A strong quarter for Entropy Neurodynamics $ENP
✅ 100% clinical response, 50% remission in Phase 2 BED study (6 patients)
✅ 72-patient, 8-indication study approved
✅ US clinical pathway advanced with UCSF
✅ BioCina manufacturing agreement
READ: https://t.co/EiDmxgG25c

[Entropy Neurodynamics @Entropy_Neuro]

ICYMI: Entropy (#ASX: $ENP) presented preliminary TRP-8803 data at ECNP: rapid, consistent psychedelic effects across 12 dosing sessions in six binge eating disorder patients, with no serious adverse events reported.

Read more: https://t.co/VM20a5msOu #biotech

[Entropy Neurodynamics @Entropy_Neuro]

Entropy (#ASX: $ENP) presented preliminary TRP-8803 data at ECNP: rapid, consistent psychedelic effects across 12 dosing sessions in six binge eating disorder patients, with no serious adverse events reported.

Read more: https://t.co/VM20a5n0E2 #biotech @ecnptweets

[Entropy Neurodynamics @Entropy_Neuro]

ICYMI: 📢 From the @InvestorStream_ desk:
@EntropyNeuro (#ASX: $ENP) cuts its TRP-8803 infusion from 140 to 60 minutes in its Phase 2 BED study
⚡ A key test of a more practical, scalable treatment model
▶️ https://t.co/N3SbgtkOgt
#Biotech $ENP.ax #ASXNews

[Entropy Neurodynamics @Entropy_Neuro]

ICYMI: Our first Cohort 2 patient completed a 60-minute TRP-8803 infusion in the Phase 2 binge eating disorder study and was safely discharged.

The cohort tests a shorter infusion, down from 140 minutes. Topline results expected by end-CY26.

https://t.co/Sd0Oz32aY8 #ASX $ENP

[Entropy Neurodynamics @Entropy_Neuro]

📢 From the @InvestorStream_ desk:
@EntropyNeuro (#ASX: $ENP) cuts its TRP-8803 infusion from 140 to 60 minutes in its Phase 2 BED study
⚡ A key test of a more practical, scalable treatment model
▶️ https://t.co/N3Sbgtlm61
#Biotech $ENP.ax #ASXNews

[Entropy Neurodynamics @Entropy_Neuro]

Our first Cohort 2 patient completed a 60-minute TRP-8803 infusion in the Phase 2 binge eating disorder study and was safely discharged.

The cohort tests a shorter infusion, down from 140 minutes. Topline results expected by end-CY26.

Read: https://t.co/Sd0Oz32ING
#ASX $ENP

[Entropy Neurodynamics @Entropy_Neuro]

ICYMI: 📎 Prenzler Group’s latest desk note on Entropy Neurodynamics (ASX: ENP) highlights TRP-8803’s 12-week binge eating disorder results, upcoming readouts and planned US depression trial.

READ MORE: https://t.co/I2YIUmtxPD

#ENP #Biotech #ClinicalTrials

[Entropy Neurodynamics @Entropy_Neuro]

📎 Prenzler Group’s latest desk note on Entropy Neurodynamics (ASX: ENP) highlights TRP-8803’s 12-week binge eating disorder results, upcoming readouts and planned US depression trial.

READ MORE: https://t.co/I2YIUmtxPD

#ENP #Biotech #ClinicalTrials

[Entropy Neurodynamics @Entropy_Neuro]

ICYMI via @StockheadAU: Tylah Tully chats with Prof Susan Rossell, principal investigator for @Entropy_Neuro binge eating disorder study, to discuss why psychedelic-assisted therapies are drawing growing attention. #ASX #Health $ENP

https://t.co/JtxgOQA561

[Entropy Neurodynamics @Entropy_Neuro]

📢 ICYMI: $ENP reports durable Phase 2 TRP-8803 results in treatment-resistant BED: all 6 patients maintained clinically meaningful improvement at 12 weeks, with weekly binge-eating episodes 73% below baseline.

READ MORE: https://t.co/1DPBFmIH0B

[Entropy Neurodynamics @Entropy_Neuro]

From the @InvestorStream_ desk:
📢 $ENP reports all 6 TRP-8803 BED patients maintained clinically meaningful improvement at 12 weeks
⚡ 50% recorded zero binge-eating episodes across 84 days, with weekly episodes 73% below baseline
📈 SP +2.5% | Vol ~1.06M #ASX #biotech

[Entropy Neurodynamics @Entropy_Neuro]

📢 $ENP reports durable Phase 2 TRP-8803 results in treatment-resistant BED: all 6 patients maintained clinically meaningful improvement at 12 weeks, with weekly binge-eating episodes 73% below baseline.

READ MORE: https://t.co/1DPBFmJeQ9

[Entropy Neurodynamics @Entropy_Neuro]

ICYMI Annual Report: FY26 saw TRP-8803 enter Phase 2 BED studies. Post year-end, all 6 Cohort 1 patients responded clinically, 3 achieved remission, and a 72-patient, 8-disorder basket study gained ethics approval. https://t.co/nZVPC4VrjG #ASX $ENP

[Entropy Neurodynamics @Entropy_Neuro]

Annual Report: FY26 saw TRP-8803 enter Phase 2 BED studies. Post year-end, all 6 Cohort 1 patients responded clinically, 3 achieved remission, and a 72-patient, 8-disorder basket study gained ethics approval. https://t.co/nZVPC4VZ9e #ASX $ENP